Clinical Trial Update: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 results for a 35 mg delayed-release formulation of risedronate in postmenopausal osteoporosis have been posted following study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Risedronate delayed-release 35 mg (risedronate)

Snippet

Sponsor: Warner Chilcott | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2011-06-21